推荐产品
等級
pharmaceutical primary standard
API 家族
mitoxantrone
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
2-8°C
SMILES 字串
Cl[H].Cl[H].OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12
InChI
1S/C22H28N4O6.2ClH/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;;/h1-4,23-30H,5-12H2;2*1H
InChI 密鑰
ZAHQPTJLOCWVPG-UHFFFAOYSA-N
基因資訊
human ... TOP2A(7153)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Mitoxantrone hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
米托蒽醌是一种细胞抑制性蒽二酮，可嵌入 DNA 中，通过稳定拓扑异构酶 II 与 DNA 的可裂解复合物，增加双链断裂的发生率。米托蒽醌还表现出广泛的免疫抑制活性，抑制各类淋巴细胞增殖并诱导抗原提呈 T 细胞凋亡。它在临床上用作抗白血病和实体瘤的化疗药物以及多发性硬化症的免疫系统调节剂。
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Danger
危險聲明
危險分類
Muta. 1B - Repr. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Hui Zhang et al.
Cancer letters, 350(1-2), 61-68 (2014-04-22)
AST1306, an inhibitor of EGFR and ErbB2, is currently in phase I of clinical trials. We evaluated the effect of AST306 on the reversal of multidrug resistance (MDR) induced by ATP-binding cassette (ABC) transporters. We found that AST1306 significantly sensitized
Jurjen M Ruben et al.
Cancer immunology, immunotherapy : CII, 63(4), 335-345 (2014-01-05)
Since few leukemia-associated antigens (LAA) are characterized for acute myeloid leukemia (AML), apoptotic tumor cells constitute an attractive LAA source for DC-based vaccines, as they contain both characterized and unknown LAA. However, loading DC with apoptotic tumor cells may interfere
Thiruganesh Ramasamy et al.
Journal of biomedical nanotechnology, 10(7), 1304-1312 (2014-05-09)
Combination of two or more drugs has emerged as a promising strategy to elicit synergistic therapeutic responses that can overcome multidrug resistance of cancer cells at various stages of the growth cycle. In the current study, we investigated the efficacy
Hann Wang et al.
ACS nano, 9(3), 3332-3344 (2015-02-18)
Combination chemotherapy can mediate drug synergy to improve treatment efficacy against a broad spectrum of cancers. However, conventional multidrug regimens are often additively determined, which have long been believed to enable good cancer-killing efficiency but are insufficient to address the
Florence Joly et al.
BJU international, 115(1), 65-73 (2013-11-05)
To evaluate the overall benefits of non-taxane chemotherapies in a non-selected population including unfit patients presenting with symptoms and pain. This randomized phase II study reports data from 92 patients (52% >70 years old; 40% with a performance score of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门